English  |  正體中文  |  简体中文  |  Post-Print筆數 : 11 |  Items with full text/Total items : 88866/118573 (75%)
Visitors : 23558974      Online Users : 217
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    政大機構典藏 > 理學院 > 心理學系 > 學位論文 >  Item 140.119/62038
    Please use this identifier to cite or link to this item: http://nccur.lib.nccu.edu.tw/handle/140.119/62038


    Title: 猝睡症患者疾病嚴重度、神經認知功能對生活品質關聯之縱貫研究:階層線性模型分析
    The Relationship between Symptom severity, Neuro-Cogntive Function and Quality of Life on Narcolepsy: A Hierarchical Linear Model study
    Authors: 王志寰
    Wang, Chih Huan
    Contributors: 楊建銘
    Yang, Chien Ming
    王志寰
    Wang, Chih Huan
    Keywords: 猝睡症
    生活品質
    嗜睡
    猝倒
    階層線性模式
    narcolepsy
    quality of life
    sleepiness
    cataplexy
    Hierarchical Linear model
    HLM
    Date: 2012
    Issue Date: 2013-12-02 17:54:06 (UTC+8)
    Abstract: 本研究旨在探討猝睡症患者生活品質受症狀變化及神經認知功能改變的影響情況,以及不同層次影響因素對患者生活品質的初始狀態及後續變化軌跡的影響效果。
    本研究於北部一所醫學中心睡眠障礙科及兒童心智科募集確診為猝睡症之患者,經同意後進行為期五年的長期研究,募集總人數168人,完成五年資料收集人數85人。本研究使用睡眠多項檢驗(polysomnography, PSG)、多段入睡測試(multiple sleep latency test, MSLT)、人類白血球抗原檢驗(human leukocyte antigen, HLA)為基本檢驗工具,以電腦化第二版康氏持續注意力測驗(Continuous Performance Test- II)及威斯康辛卡片分類測驗(Wisconsin Card Sorting Test, WCST)為檢測神經認知功能之工具,以自填艾普渥斯嗜睡程度量表(Epworth sleepiness scale, ESS)、史丹佛睡眠問卷(Stanford sleep inventory, SSI)及簡式生活品質量表(short from-36 items of health related quality of life, SF-36)做為症狀嚴重度及生活品質的依據。資料分析以描述統計及階層線性模式(hierarchical linear models , HLM)統計方法進行。主要結果如下:
    一、 猝睡症患者生活品質分為生理與心理兩個層面,患者生理層面在五年期間維持相對穩定沒有顯著變化;心理層面中之不同向度則有不同變化趨勢,心理健康與活力向度隨時間有逐漸提高的趨勢,患者此二向度生活品質接受治療後有穩定上升的趨勢,而社會功能及情緒角色限制則呈現二次方曲線變化,以及呈現先增後減的發展軌跡,患者此二向度接受治療後顯著上升,第三年後有逐年下降的趨勢。
    二、 患者嗜睡程度及猝倒嚴重度變化隨時間有顯著成長軌跡,呈二次方曲線發展,轉折點在第三年,接受治療前三年症狀呈現穩定降低的軌跡,但自第三年起逐年增加,此結果與藥物治療初期症狀獲得顯著改善,後期改善幅度相對減少,及藥物效果具有關聯。
    三、 個體間層次變項僅疾病持續時間、HLA對患者生活品質具顯著解釋力,其中疾病持續時間越長,患者可能發展因應症狀之策略,從而降低疾病對生活品質之衝擊。而HLA則對症狀有不同影響,HLA陽性患者初始嗜睡程度較陰性者為低,且接受治療後改善效果較陰性者顯著,猝倒嚴重度起始值較陰性者高,且接受治療後的趕善幅度較陰性者小。
    四、 疾病嚴重度變化對生活品質具顯著影響,完整模式分析中,時間主效應未達顯著,但可由症狀變化及神經認知功能改變進行更佳的解釋。嗜睡程度變化僅對身體疼痛向度變化不具有解釋力外,對其餘七個向度均具顯著影響;猝倒影響層面不及嗜睡程度,但亦可解釋生理量表、生理角色限制、心理量表、心理健康、情緒角色限制、活力等向度上的變化。
    五、 神經認知功能改變與否對患者生活品質具有加成效果,分析顯示患者神經認知功能改善時,其生活品質提升速率較未改善者高,影響較顯著的包括注意力、警覺度及概念反應,此結果與下視丘泌素參與的維持注意力及前額葉功能有關。
    本研究依據分析結果提出猝睡症患者生活品質受嗜睡症狀及猝倒嚴重度改變直接影響,同時受人類白血球抗原屬性及神經認知功能改變調節之假設模型,作為未來研究參考依據。並根據研究結果與限制,提出對臨床實務的應用與心理介入的建議,並對未來提升猝睡症患者生活品質相關研究提供建議。
    The current study aims to: (1) examine the change of eight domains of quality of life in narcoleptics within five years, (2) investigate the impact of the change of symptom severity on different dimension of quality of life, as well as the influence associated with the change of neuro-cognitive function.
    There were 168 participants recruited from a medical center in northern Taiwan. 85 of them completed the 5-year annual follow-up data collection. During the follow-ups, polysomnography (PSG), multiple sleep latency test (MSLT) and human leukocyte antigen (HLA) test were conducted. Computerized neuropsychological tests of Conners’ Continuous Performance Test- II (CPT-II) and Wisconsin Card Sorting Test (WCST) were also administered to obtain attention and executive function data. The short from-36 items of health related quality of life (SF-36), Stanford sleep inventory (SSI) and Epworth sleepiness scale were applied to assess quality of life and symptom severity. Descriptive statistics and hierarchical linear models were applied for data analysis. The main results were:
    1. The quality of life was divided into physical and psychological domains. The physical domain kept relatively stable during the 5-year follow up as opposed to the psychological domain. In psychological domain, the vitality and psychological health showed increasing tendency overtime. However, the social function and role functioning-emotion increased during the first 3 years then declined afterward.
    2. The symptom severity also showed a tendency corresponded to quadratic curve. The daytime sleepiness together with cataplexy severity reduced immediately after treatment but rose after the third year.
    3. The variables of individual characteristics that showed significant impact on quality of life were disease duration and HLA type. The longer the duration, the better quality of life one had. Positive HLA typing seemed to be a protective factor on severity of sleepiness. It also predicted better treatment outcomes, but worsen the severity of cataplexy and treatment effects.
    4. The symptom severity could be a good explanation as a variable of quality of life. The daytime sleepiness altered all domain of SF-36 expect body pain. Cataplexy affected only psychological domain of SF-36.
    5. The neuro-cognitive function was also found to affect quality of life. Those who improved in attention and executive function test got greater improvement on SF-36 as well. The vigilance on CPT-II and conceptualized response on WCST had most significant impact.
    I proposed a model of change of quality of life in patients with narcolepsy based on the results obtained. Several suggestions were also proposed for clinical and psychological intervention for narcolepsy to improve their quality of life.
    Reference: AASM. (2005). The International Classification of Sleep Disorders: diagnostic and coding manual. 2nd Ed. Westchester, IL: AASM.
    Akintomide, G. S., & Rickards, H. (2011). Narcolepsy: a review. Neuropsychiatr Dis Treat, 7, 507-518.
    Anic-Labat, C., Guilleminault, C., Kraemer, H., Meehan, J., Arrigoni, J., & Mignot, E. (1999). Validation of a Cataplexy Questionnaire in 983 Sleep-disorders Patients. Sleep, 19, 77-87.
    Albert, W., Hudalla, A., Traue, K., & Hetzer, R. (2012). Impact of heart transplantation in infancy and adolescence on quality of life and compliance. HSR Proc Intensive Care Cardiovasc Anesth, 4(2), 125-129.
    Aldrich, M. S. (1998). Diagnostic aspects of narcolepsy. [Review]. Neurology, 50(2 Suppl 1), S2-7.
    Allen, M. D., Hedges, D. W., Farrer, T. J., & Larson, M. J. (2012). Assessment of brain activity during memory encoding in a narcolepsy patient on and off modafinil using normative fMRI data. [Case Reports]. Neurocase, 18(1), 13-25.
    Andlauer, O., Moore, H. t., Hong, S. C., Dauvilliers, Y., Kanbayashi, T., Nishino, S., . . . Mignot, E. (2012). Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. Sleep, 35(9), 1247-1255F.
    Ando, A., Shigenari, A., Naruse, T. K., Sugaya, K., Juji, T., Honda, Y., Inoko, H. (1997). Triplet repeat polymorphism within the NOTCH4 gene located near the junction of the HLA class II and class III regions in narcolepsy. Tissue Antigens, 50(6), 646-649.
    Arii, J., Kanbayashi, T., Tanabe, Y., Sawaishi, Y., Kimura, S., Watanabe, A., Nishino, S. (2004). CSF hypocretin-1 (orexin-A) levels in childhood narcolepsy and neurologic disorders. [Review]. Neurology, 63(12), 2440-2442.
    Baier, P. C., Hallschmid, M., Seeck-Hirschner, M., Weinhold, S. L., Burkert, S., Diessner, N., . . . Hinze-Selch, D. (2011). Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy. Sleep Medicine, 12(10), 941-946.
    Bajaj J. S. (2008) Minimal hepatic encephalopathy matters in daily life. World Journal Gastroenterol. 14(23): 3609–3615.
    Bassetti, C., & Aldrich, M. S. (1996). Narcolepsy. [Review]. Neurology Clinic, 14(3), 545-571.
    Baumann, C. R., Khatami, R., Werth, E., & Bassetti, C. L. (2006). Hypocretin (orexin) deficiency predicts severe objective excessive daytime sleepiness in narcolepsy with cataplexy. Journal of Neurol Neurosurg Psychiatry, 77(3), 402-404.
    Bayard, S., Abril, B., Yu, H., Scholz, S., Carlander, B., & Dauvilliers, Y. (2011). Decision Making in Narcolepsy with Cataplexy. SLEEP, 34(1), 99-104.
    Bayard, S., Croisier Langenier, M., Cochen De Cock, V., Scholz, S., & Dauvilliers, Y. (2012). Executive control of attention in narcolepsy. PLoS One, 7(4), e33525.
    Becker, P. M., Schwartz, J. R., Feldman, N. T., & Hughes, R. J. (2004). Effect of modafinil on fatigue, mood, and health-related quality of life in patients with narcolepsy. Psychopharmacology (Berl), 171(2), 133-139.
    Bernardini, C., Lattanzi, W., Bosco, P., Franceschini, C., Plazzi, G., Michetti, F., & Ferri, R. (2012). Genome-wide gene expression profiling of human narcolepsy. Gene Express, 15(4), 171-181.
    Berry, R. B. (2012). Fundamental of Sleep Medicineicine. Philadelphia, PA: Elsevier.
    Berton, D. C., Silveira, L., Da Costa, C. C., De Souza, R. M., Winter, C. D., & Zimermann Teixeira, P. J. (2013). Effectiveness of Pulmonary Rehabilitation in Exercise Capacity and Quality of Life in Chronic Obstructive Pulmonary Disease Patients With and Without Global Fat-Free Mass Depletion. Arch Phys Medicine Rehabil.
    Beusterien, K. M., Rogers, A. E., Walsleben, J. A., Emsellem, H. A., Reblando, J. A., Wang, L., Steinwald, B. (1999). Health-related quality of life effects of modafinil for treatment of narcolepsy. Sleep, 22(6), 757-765.
    Black, J., & Guilleminault, C. (2001). Medicineications for the treatment of narcolepsy. Expert Opin Emerg Drugs, 6(2), 239-247.
    Broughton, R., Ghanem, Q., Hishikawa, Y., Sugita, Y., Nevsimalova, S., & Roth, B. (1981). Life effects of narcolepsy in 180 patients from North America, Asia and Europe compared to matched controls. Can Journal of Neurology Science, 8(4), 299-304.
    Broughton, R., Ghanem, Q., Hishikawa, Y., Sugita, Y., Nevsimalova, S., & Roth, B. (1983). Life effects of narcolepsy: relationships to geographic origin (North American, Asian or European) and to other patient and illness variables. Journal of Neurology Science, 10(2), 100-104.
    Broughton, R. J. (1992). Psychosocial impact of Narcolepsy with Cataplexy with Comparisons to Idoiopathic Hypersomnia and Epilepsy. USA, NY.: Haworth Press.
    Bruck, D. (2001). The impact of narcolepsy on psychological health and role behaviours: negative effects and comparisons with other illness groups. Sleep Medicine, 2(5), 437-446.
    Brown, T. E., & Landgraf, J. M. (2010). Improvements in executive function correlate with enhanced performance and functioning and health-related quality of life: evidence from 2 large, double-blind, randomized, placebo-controlled trials in ADHD. [Randomized Controlled Trial]. Postgrad Medicine, 122(5), 42-51.
    Campbell, A. J., Signal, T. L., O'Keeffe, K. M., & Bakker, J. P. (2011). Narcolepsy in New Zealand: pathway to diagnosis and effect on quality of life.. MedicineJournal, 124(1336), 51-61.
    Carskadon MA, Dement WC, Mitler MM, Roth T, Westbrook PR,Keenan S. Guidelines for the multiple sleep latency test (MSLT): a standardmeasure of sleepiness. Sleep 1986;9:519-524.
    Cao, M. (2010). Advances in narcolepsy. [Review]. Medicine Clinic North American, 94(3), 541-555.
    Challamel, M. J., Mazzola, M. E., Nevsimalova, S., Cannard, C., Louis, J., & Revol, M. (1994). Narcolepsy in children. [Comparative Study]. Sleep, 17(8 Suppl), S17-20.
    Chen, G., Zhou, X., Hu, X., Liu, Y., & Li, Q. (2011). [Effect of exercise on the quality of life and pulmonary function in patients with chronic obstructive pulmonary disease]. Zhong Nan Da Xue Xue Bao Yi Xue Ban, 36(7), 682-686.
    Coelho, F. M., Pradella-Hallinan, M., Predazzoli Neto, M., Bittencourt, L. R., & Tufik, S. (2009). Prevalence of the HLA-DQB1*0602 allele in narcolepsy and idiopathic hypersomnia patients seen at a sleep disorders outpatient unit in Sao Paulo. Review Bras Psiquiatr, 31(1), 10-14.
    Golicki, D., Bala, M. M., Niewada, M., & Wierzbicka, A. (2010). Modafinil for narcolepsy: systematic review and meta-analysis. Medicine Science Monit, 16(8), RA177-186.
    Cortesi, P. A., Mencacci, C., Luigi, F., Pirfo, E., Berto, P., Sturkenboom, M. C., . . . Scalone, L. (2013). Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study. BMC Psychiatry, 13, 98. vol: 10.1186
    Dahlitz, M., Vaughan, R., Kayed, K., & Parkes, J. D. (1992). The narcolepsy susceptibility gene. Lancet, 339(8804), 1297.
    Dalal, M. A., Schuld, A., & Pollmacher, T. (2002). Undetectable CSF level of orexin A (hypocretin-1) in a HLA-DR2 negative patient with narcolepsy-cataplexy. Journal ofSleep Res, 11(3), 273.
    Daniels, E., King, M. A., Smith, I. E., & Shneerson, J. M. (2001). Health-related quality of life in narcolepsy. Journal Sleep Research, 10(1), 75-81.
    Dauvilliers, Y., Montplaisir, J., Molinari, N., Carlander, B., Ondze, B., Besset, A., & Billiard, M. (2001). Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology, 57(11), 2029-2033.
    David, A., Constantino, F., dos Santos, J. M., & Paiva, T. (2012). Health-related quality of life in Portuguese patients with narcolepsy. Sleep Medicine, 13(3), 273-277. do
    Delazer, M., Hogl, B., Zamarian, L., Wenter, J., Gschliesser, V., Ehrmann, L., Frauscher, B. (2011). Executive functions, information sampling, and decision making in narcolepsy with cataplexy. Neuropsychology, 25(4), 477-487.
    Dickson, A., Toft, A., & O'Carroll, R. E. (2009). Neuropsychological functioning, illness perception, mood and quality of life in chronic fatigue syndrome, autoimmune thyroid disease and healthy participants. PsychologyMedicine, 39(9), 1567-1576.
    Dimitrova, A., Fronczek, R., Van der Ploeg, J., Scammell, T., Gautam, S., Pascual-Leone, A., & Lammers, G. J. (2011). Reward-seeking behavior in human narcolepsy. JournalClinical Sleep Medicine, 7(3), 293-300.
    Dodel, R., Peter, H., Spottke, A., Noelker, C., Althaus, A., Siebert, U.,Mayer, G. (2007). Health-related quality of life in patients with narcolepsy. Sleep Medicine, 8(7-8), 733-741
    Doherty, L., Crowe, C., & Sweeney, B. (2010). National narcolepsy survey. Ir MedicineJournal, 103(4), 110, 112-113.
    Droogleever Fortuyn, H. A., Fronczek, R., Smitshoek, M., Overeem, S., Lappenschaar, M., Kalkman, J.,Bleijenberg, G. (2012). Severe fatigue in narcolepsy with cataplexy. Journal Sleep Research, 21(2), 163-169.
    Feldman, G. J. (2013). Improving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterol. Int Journal Chron Obstruct Pulmon Dis, 8, 89-96.
    Ferrans, C. E. (1990). Quality of life: conceptual issues. Semin Oncology Nursery, 6(4), 248-254.
    Ferrans, C. E., & Powers, M. J. (1992). Psychometric assessment of the Quality of Life Index. Research Nursery Health, 15(1), 29-38.
    Finkel, S. E. (1995). Causal analysis with panel data. CA: Sage Publications.
    Fortuyn, H. A., Swinkels, S., Buitelaar, J., Renier, W. O., Furer, J. W., Rijnders, C. A., Overeem, S. (2008). High prevalence of eating disorders in narcolepsy with cataplexy: a case-control study. Sleep, 31(3), 335-341.
    Fronczek, R., Middelkoop, H. A., van Dijk, J. G., & Lammers, G. J. (2006). Focusing on vigilance instead of sleepiness in the assessment of narcolepsy: high sensitivity of the Sustained Attention to Response Task (SART). Sleep, 29(2), 187-191.
    Fronczek, R., Raymann, R. J., Romeijn, N., Overeem, S., Fischer, M., van Dijk, J. G., Van Someren, E. J. (2008). Manipulation of core body and skin temperature improves vigilance and maintenance of wakefulness in narcolepsy. Sleep, 31(2), 233-240.
    George, C. F., Boudreau, A. C., & Smiley, A. (1996). Comparison of simulated driving performance in narcolepsy and sleep apnea patients. Sleep, 19(9), 711-717.
    Gigliotti, F., Grazzini, M., Stendardi, L., Romagnoli, I., & Scano, G. (2002). Quality of life and functional parameters in patients with chronic obstructive pulmonary disease (COPD): an update. [Review]. RespiratoryMedicine, 96(6), 373-374.
    Guilleminault, C. (1993). Amphetamines and narcolepsy: use of the Stanford database. Sleep, 16(3), 199-201.
    Guilleminault, C., Billiard, M., Montplaisir, J., & Dement, W. (1975). Altered states of consciousness in disorder of daytime sleepiness. Journal of Neuro-Science., 26, 377-393.
    Guilleminault, C., Mignot, E., Aldrich, M., Quera-Salva, M. A., Tiberge, M., & Partinen, M. (1988). Prazosin contraindicated in patients with narcolepsy. Lancet, 2(8609), 511.
    Han, F., Chen, E. Z., Wei, H. L., Dong, X. S., Li, J., Li, M., Ding, D. J. (2003). [HLA-DRB and -DQB allele contribution to narcolepsy susceptibility in Chinese patients with narcolepsy]. Zhonghua Yi Xue Za Zhi, 83(8), 644-646.
    Hara, J., Beuckmann, C. T., Nambu, T., Willie, J. T., Chemelli, R. M., Sinton, C. M., Sakurai, T. (2001). Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron, 30(2), 345-354.
    Harsh, J. R., Hayduk, R., Rosenberg, R., Wesnes, K. A., Walsh, J. K., Arora, S., Roth, T. (2006). The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. CurrentMedicine Research Opinuon, 22(4), 761-774.
    Hsiao, C. (1989). Analysis of panel data.: Cambridge University Press.
    Huang, Y. S., & Guilleminault, C. (2009). Narcolepsy: action of two gamma-aminobutyric acid type B agonists, baclofen and sodium oxybate. Pediatr Neurolohy, 41(1), 9-16. doi: 10.1016/j.pediatrneurol.2009.02.008
    Huda, M. S., Mani, H., Durham, B. H., Dovey, T. M., Halford, J. C., Aditya, B. S., Hart, I. K. (2013). Plasma obestatin and autonomic function are altered in orexin-deficient narcolepsy, but ghrelin is unchanged. Endocrine, 43(3), 696-704.
    Hungs, M., & Mignot, E. (2001). Hypocretin/orexin, sleep and narcolepsy. Bioessays, 23(5), 397-408. doi: 10.1002/bies.1058
    Jacobsen, P. B., & Jim, H. S. (2011). Consideration of quality of life in cancer survivorship research. [Review]. Cancer Epidemiol Biomarkers Prev, 20(10), 2035-2041.
    Johns, M. W. (1991). A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep, 14(6), 540-545.
    Johns, M. W. (1992). Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep, 15(4), 376-381.
    Johns, M. W. (1993). Daytime sleepiness, snoring, and obstructive sleep apnea. The Epworth Sleepiness Scale. Chest, 103(1), 30-36.
    Johns, M. W. (1994). Sleepiness in different situations measured by the Epworth Sleepiness Scale. [Comparative Study]. Sleep, 17(8), 703-710.
    Joo, E. Y., Seo, D. W., Tae, W. S., & Hong, S. B. (2008). Effect of modafinil on cerebral blood flow in narcolepsy patients. Sleep, 31(6), 868-873.
    Juji, T., Satake, M., Honda, Y., & Doi, Y. (1984). HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. [Comparative Study]. Tissue Antigens, 24(5), 316-319.
    Kales, A., Soldatos, C. R., Bixler, E. O., Caldwell, A., Cadieux, R. J., Verrechio, J. M., & Kales, J. D. (1982). Narcolepsy-cataplexy. II. Psychosocial consequences and associated psychopathology. Arch Neurology, 39(3), 169-171.
    Krahn, L. E., Pankratz, V. S., Oliver, L., Boeve, B. F., & Silber, M. H. (2002). Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status. Sleep, 25(7), 733-736.
    Kawashima, M., Lin, L., Tanaka, S., Jennum, P., Knudsen, S., Nevsimalova, S., . . . Mignot, E. (2010). Anti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy. Sleep, 33(7), 869-874.
    Klein, G., Burghaus, L., & Diederich, N. (2012). [Pathogenesis of narcolepsy: from HLA association to hypocretin deficiency]. [Review]. Fortschr Neurology Psychiatry, 80(11), 627-634.
    Kornum, B. R., Faraco, J., & Mignot, E. (2011). Narcolepsy with hypocretin/orexin deficiency, infections and autoimmunity of the brain. [Review]. Curr Opin Neurobioogyl, 21(6), 897-903.
    Krahn, L. E., Pankratz, V. S., Oliver, L., Boeve, B. F., & Silber, M. H. (2002). Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1*0602 status. Sleep, 25(7), 733-736.
    Lim, A. S., & Scammell, T. E. (2010). The trouble with Tribbles: do antibodies against TRIB2 cause narcolepsy? [Comment]. Sleep, 33(7), 857-858.
    Lecendreux, M., Bruni, O., Franco, P., Gringras, P., Konofal, E., Nevsimalova, S.,Poli, F. (2012). Clinical experience suggests that modafinil is an effective and safe treatment for paediatric narcolepsy. Journal Sleep Research, 21(4), 481-483.
    Longstreth, W. T., Jr., Koepsell, T. D., Ton, T. G., Hendrickson, A. F., & van Belle, G. (2007). The epidemiology of narcolepsy. Sleep, 30(1), 13-26.
    Mignot, E., Guilleminault, C., Bowersox, S., Frusthofer, B., Nishino, S., Maddaluno, J., Dement, W. C. (1989). Central alpha 1 adrenoceptor subtypes in narcolepsy-cataplexy: a disorder of REM sleep. Brain Research, 490(1), 186-191.
    Mignot, E., Guilleminault, C., Bowersox, S., Rappaport, A., & Dement, W. C. (1988). Effect of alpha 1-adrenoceptors blockade with prazosin in canine narcolepsy. Brain Research, 444(1), 184-188.
    Mitler, M. M., Harsh, J., Hirshkowitz, M., & Guilleminault, C. (2000). Long-term efficacy and safety of modafinil (PROVIGIL((R))) for the treatment of excessive daytime sleepiness associated with narcolepsy. Sleep Medicine, 1(3), 231-243.
    Moreno-Iniguez, M., Ortuno, F., Arbizu, J., Millan, M., Soutullo, C., & Cervera-Enguix, S. (2005). Regional cerebral blood flow SPECT study, at rest and during Wisconsin Card Sorting Test (WCST) performance, in schizophrenia naive patients or treated with atypical neuroleptics. Actas Esp Psiquiatr, 33(6), 343-351.
    Moreira, F., Pedrazzoli, M., Dos Santos Coelho, F. M., Pradella-Hallinan, M., Lopes da Conceicao, M. C., Pereira Peregrino, A. J.,Tufik, S. (2005). Clock gene polymorphisms and narcolepsy in positive and negative HLA-DQB1*0602 patients. Brain Res Mol Brain Research, 140(1-2), 150-154.
    Moscovitch A, Partinen M, Guilleminault C. The positive diagnosis ofnarcolepsy and narcolepsy's borderland. Neurology 1993;43:55-60.
    Muntner, P., Sudre, P., & Perneger, T. V. (2000). Comparison of the psychometric properties of the Asthma Quality of life Questionnaire (AQLQ) among 115 asthmatic adults assessed during acute hospitalization and as outpatients. . Quality Life Research, 9(9), 987-995.
    Nakamura, M., Kanbayashi, T., Sugiura, T., & Inoue, Y. (2011). Relationship between clinical characteristics of narcolepsy and CSF orexin-A levels. Journal Sleep Research, 20(1 Pt 1), 45-49.
    Naumann, A., Bellebaum, C., & Daum, I. (2006). Cognitive deficits in narcolepsy. JournalSleep Research. 15, 329-338.
    Nevsimalova, S. (2009). Narcolepsy in childhood. Sleep Medicine Review, 13(2), 169-180.
    Nevsimalova, S., Jara, C., Prihodova, I., Kemlink, D., Sonka, K., & Skibova, J. (2011). Clinical features of childhood narcolepsy. Can cataplexy be foretold? Eur Journal Paediatr Neurol, 15(4), 320-325.
    Nishino, S., Okuro, M., Kotorii, N., Anegawa, E., Ishimaru, Y., Matsumura, M., & Kanbayashi, T. (2010). Hypocretin/orexin and narcolepsy: new basic and clinical insights.(Oxford), 198(3), 209-222.
    Ohayon, M. M., Priest, R. G., Zulley, J., Smirne, S., & Paiva, T. (2002). Prevalence of narcolepsy symptomatology and diagnosis in the European general population. Neurology, 58(12), 1826-1833.
    Olerup, O., Schaffer, M., Hillert, J., & Sachs, C. (1990). The narcolepsy-associated DRw15,DQw6,Dw2 haplotype has no unique HLA-DQA or -DQB restriction fragments and does not extend to the HLA-DP subregion. Immunogenetics, 32(1), 41-44.
    Overeem, S., van Nues, S. J., van der Zande, W. L., Donjacour, C. E., van Mierlo, P., & Lammers, G. J. (2011). The clinical features of cataplexy: a questionnaire study in narcolepsy patients with and without hypocretin-1 deficiency. Sleep Medicine, 12(1), 12-18.
    Ozaki, A., Inoue, Y., Hayashida, K., Nakajima, T., Honda, M., Usui, A., Takahashi, K. (2012). Quality of life in patients with narcolepsy with cataplexy, narcolepsy without cataplexy, and idiopathic hypersomnia without long sleep time: comparison between patients on psychostimulants, drug-naive patients and the general Japanese population. Sleep Medicine, 13(2), 200-206.
    Ozaki, A., Inoue, Y., Nakajima, T., Hayashida, K., Honda, M., Komada, Y., & Takahashi, K. (2008). Health-related quality of life among drug-naive patients with narcolepsy with cataplexy, narcolepsy without cataplexy, and idiopathic hypersomnia without long sleep time. J Clin Sleep Medicine, 4(6), 572-578.
    Palaia, V., Poli, F., Pizza, F., Antelmi, E., Franceschini, C., Moghadam, K. K., . . . Plazzi, G. (2011). Narcolepsy with Cataplexy Associated with Nocturnal Compulsive Behaviors:A Case-Control Study. Sleep., 34(10). 1365-1371.
    Pedersen, A., Wilmsmeier, A., Wiedl, K. H., Bauer, J., Kueppers, K., Koelkebeck, K., Ohrmann, P. (2012). Anterior cingulate cortex activation is related to learning potential on the WCST in schizophrenia patients. Brain Cognition, 79(3), 245-251.
    Peraita-Adrados, R., Ezpeleta, D., Balas, A., & Vicario, J. L. (1999). Narcolepsy-cataplexy syndrome associated with DRB1*0806-DQB*0602 haplotype in a Caucasian patient. Sleep Research Online, 2(2), 29-31.
    Perneger, T. V., & Hudelson, P. M. (1995). The quality of quality-of-life measurements. JAMA, 273(11), 843-844.
    Planelles, D., Puig, N., Beneto, A., Gomez, E., Rubio, P., Mirabet, V., Montoro, J. A. (1997). HLA-DQA, -DQB and -DRB allele contribution to narcolepsy susceptibility. EuropJournalImmunogenet, 24(6), 409-421.
    Ray, K. (2010). Sleep: Narcolepsy--a role for TRIB2 autoantibodies? [Comment]. Nat Review Neurology, 6(5), 238.
    Riccioni, G., Prencipe, G., Benvenuto, A., Masciocco, L., Ventra, S., Rizzo, U., Speziale, G. (2013). Ivabradine improves all aspects of quality of life assessed with the 36-item short form health survey in subjects with chronic ischemic heart disease compared with beta-blockers. Pharmacology, 91(1-2), 35-38.
    Rieger, M., Mayer, G., & Gauggel, S. (2003). Attention deficits in patients with narcolepsy. Sleep, 26(1), 36-43.
    Rovere, H., Rossini, S., & Reimao, R. (2008). Quality of life in patients with narcolepsy: a WHOQOL-bref study. Arq Neuropsiquiatr, 66(2A), 163-167.
    Ruiz-Diaz, M., Hernandez-Gonzalez, M., Guevara, M. A., Amezcua, C., & Agmo, A. (2012). Prefrontal EEG correlation during Tower of Hanoi and WCST performance: effect of emotional visual stimuli. Journal Sex Medicine, 9(10), 2631-2640.
    Sanna G, Petralia G, Cossu Rocca M, Marenghi C, Nolè F. (2008) Long Survival in a Patient with Brain Metastases from Breast Cancer.Clinical Medicineicine: Oncology Vol.2 P.103–108
    Schoemaker, K., Bunte, T., Wiebe, S. A., Espy, K. A., Dekovic, M., & Matthys, W. (2012). Executive function deficits in preschool children with ADHD and DBD. [Comparative Study]. Journal Child Psychol Psychiatry, 53(2), 111-119.
    Schulz, H., & Wild-Frenz, J. (1995). The disturbance of cognitive processes in narcolepsy. Journal of Sleep Research., 4, 10-14.
    Schwartz, J. R., Nelson, M. T., Schwartz, E. R., & Hughes, R. J. (2004). Effects of modafinil on wakefulness and executive function in patients with narcolepsy experiencing late-day sleepiness. Clinical Neuropharmacol, 27(2), 74-79.
    Shin, Y. K., Yoon, I. Y., Han, E. K., No, Y. M., Hong, M. C., Yun, Y. D., Hong, S. C. (2008). Prevalence of narcolepsy-cataplexy in Korean adolescents. Acta Neurology Scand, 117(4), 273-278. doi: 10.1111/j.1600-0404.2007.00930.x
    Siegel, J. M., Moore, R., Thannickal, T., & Nienhuis, R. (2001). A brief history of hypocretin/orexin and narcolepsy. Neuropsychopharmacology, 25(5 Suppl), S14-20.
    Solon, G. (1989). The value of panel data in economic research. New York: John Wiley & Sons, Inc.
    Stores, G., Montgomery, P., & Wiggs, L. (2006). The psychosocial problems of children with narcolepsy and those with excessive daytime sleepiness of uncertain origin.Pediatrics, 118(4), e1116-1123.
    Teixeira VG, Faccenda JF, Douglas NJ. Functional status inpatients with narcolepsy. Sleep Medicine 2004;5(5):477–83.
    Vignatelli, L., D'Alessandro, R., Mosconi, P., Ferini-Strambi, L., Guidolin, L., De Vincentiis, A., & Plazzi, G. (2004). Health-related quality of life in Italian patients with narcolepsy: the SF-36 health survey. Sleep Medicine, 5(5), 467-475.
    Vignatelli, L., Plazzi, G., Peschechera, F., Delaj, L., & D'Alessandro, R. (2011). A 5-year prospective cohort study on health-related quality of life in patients with narcolepsy. Sleep Medicine, 12(1), 19-23.
    Volz, H. P., Gaser, C., Hager, F., Rzanny, R., Mentzel, H. J., Kreitschmann-Andermahr, I., Sauer, H. (1997). Brain activation during cognitive stimulation with the Wisconsin Card Sorting Test--a functional MRI study on healthy volunteers and schizophrenics. . Psychiatry Research, 75(3), 145-157.
    Wasserfallen, J. B., Halabi, G., Saudan, P., Perneger, T., Feldman, H. I., Martin, P. Y., & Wauters, J. P. (2004). Quality of life on chronic dialysis: comparison between haemodialysis and peritoneal dialysis. Nephrol Dial Transplant, 19(6), 1594-1599.
    Watson, N. F., Ton, T. G., Koepsell, T. D., Gersuk, V. H., & Longstreth, W. T., Jr. (2010). Does narcolepsy symptom severity vary according to HLA-DQB1*0602 allele status? Sleep, 33(1), 29-35.
    Wieczorek, S., Dahmen, N., Kasten, M., Epplen, J. T., & Gencik, M. (2004). A rare form of narcolepsy (HLA-DR2-) shows possible association with (functionally relevant) alpha-interferon gene polymorphisms. Psychiatry Genet, 14(1), 47-51.
    Wilson, S. J., Frazer, D. W., Lawrence, J. A., & Bladin, P. F. (2007). Psychosocial adjustment following relief of chronic narcolepsy. Sleep Medicine, 8(3), 252-259.
    王拔群、李學禹、莊銘隆、黃玉書、陳彥宏、邱國樑、陳濘宏 (2003) 中文版Epworth嗜睡量表之信效度研究. 臺灣精神醫學, 17:1, 14-22.
    吳齊殷、張明宜、陳怡蒨 (2008) 尋找機制與過程:長期追蹤研究的功用. 量化研究學刊, 第二卷(一), 1-26.
    邱皓政(2007)脈絡變數的多層次潛在變數模式分析。中華心理學刊。49卷,4期,383-405
    郭志剛 (2008) 階層線性模式. Taipei, Taiwan: 五南出版社.
    盧瑞芬、曾旭民、蔡益堅 (2003) 國人生活品質評量(I):SF-36台灣版的發展及心理計劃特質分析. 台灣公共衛生雜誌, 22(6), 501-511.
    曾旭民、盧瑞芬、蔡益堅(2003)國人生活品質評量(Ⅱ):SF-36台灣版的常模與效度檢測. 台灣公共衛生雜誌, Vol.22 No.6. P.512-518
    Description: 博士
    國立政治大學
    心理學研究所
    93752502
    101
    Source URI: http://thesis.lib.nccu.edu.tw/record/#G0937525021
    Data Type: thesis
    Appears in Collections:[心理學系] 學位論文

    Files in This Item:

    File Description SizeFormat
    502101.pdf1229KbAdobe PDF1423View/Open


    All items in 政大典藏 are protected by copyright, with all rights reserved.


    社群 sharing

    著作權政策宣告
    1.本網站之數位內容為國立政治大學所收錄之機構典藏,無償提供學術研究與公眾教育等公益性使用,惟仍請適度,合理使用本網站之內容,以尊重著作權人之權益。商業上之利用,則請先取得著作權人之授權。
    2.本網站之製作,已盡力防止侵害著作權人之權益,如仍發現本網站之數位內容有侵害著作權人權益情事者,請權利人通知本網站維護人員(nccur@nccu.edu.tw),維護人員將立即採取移除該數位著作等補救措施。
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback